George Yancopoulos

Last updated
George Yancopoulos
George Yancopoulos.jpg
Born1959 (age 6465)
Education Columbia University (BA, MD, PhD)
OccupationBiomedical scientist
Employer Regeneron

George D. Yancopoulos (born 1959) is a Greek-American biomedical scientist who is the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals. [1]

Contents

Yancopoulos is the holder of more than 100 patents. [2] He is a principal inventor and developer of Regeneron's ten FDA-approved or -authorized treatments, as well as of Regeneron's foundational technologies for target and drug development, such as its proprietary TRAP technology, and the VelociGene and VelocImmune antibody technologies. [3] [4]

Early life and education

Son of Greek immigrants he spent his early childhood in Woodside, New York. As a student at the Bronx High School of Science, Yancopoulos was a top winner of the 1976 Westinghouse Science Talent Search. Intel and then Regeneron later assumed the title sponsorship for the Science Talent Search. [5]

After graduating as valedictorian of both the Bronx High School of Science and Columbia College, Yancopoulos received his MD and PhD degrees in 1987 from Columbia University's College of Physicians & Surgeons. He then worked in the field of molecular immunology at Columbia University with Dr. Fred Alt, for which he received the Lucille P. Markey Scholar Award. [6]

He currently resides in Yorktown Heights. [7]

Scientific career

Based on his scientific publications, he was elected to both the National Academy of Sciences [6] and the American Academy of Arts and Sciences in 2004. According to a study by the Institute for Scientific Information, he was the eleventh most highly cited scientist in the world during the 1990s, and the only scientist from the biotechnology industry on the list. [8]

Yancopoulos has cloned novel families of growth factors, including ephrins/Ephs and angiopoietins, and elucidated the basis of how many receptors work. [9] His work has included study of how nerves regenerate [6] and how muscles connect to nerves. [10]

In 1985, along with his mentor Dr. Fred Alt, he was the first to propose making mouse models with genetically human immune systems ("Human mice"). [11] This research led to Yancopoulos developing "the most valuable mouse ever made," bred to have immune systems that respond just as a human's would, so that it can be used for testing how the human body might react to various pharmaceuticals and other substances. [6]

Much of Yancopoulos and Alt's work in immunology including common recombination, accessibility control of recombination and scanning or tracking of recombinant action, has been recently validated. [12]

Career

Yancopoulos left academia in 1989 to become the founding scientist and chief scientific officer of Regeneron Pharmaceuticals with founder and chief executive officer Leonard Schleifer, M.D., Ph.D. In 2016, Yancopoulos was also named president of the company. [13]

Yancopoulos plays an active role in Regeneron's STEM (Science, Technology, Engineering and Math) Education commitments, including the Regeneron Science Talent Search, the nation's oldest high school science and math competition. [14]

In 2014, Yancopoulos led the launch of the Regeneron Genetics Center, a major initiative in human genetic research that has sequenced exomes from over 1,000,000 people as of February 2020. [15] [16]

Forbes magazine states Yancopoulos' financial stake in Regeneron has made him a billionaire. He is the first research and development chief in the pharmaceutical industry to become a billionaire. [17]

Awards

Yancopoulos won a NY/NJ CEO Lifetime Achievement Award in 2012. [18]

Yancopoulos has been awarded Columbia University's Stevens Triennial Prize for Research and its University Medal of Excellence for Distinguished Achievement. [19]

In 2016, Leonard Schleifer and George Yancopoulos were named the Ernst & Young Entrepreneurs of the Year 2016 National Award Winners in life sciences. [20]

The George D. Yancopoulos Young Scientist Award is given at the Westchester Science & Engineering Fair. [21]

He was inducted into the Bronx Science Hall of Fame in 2017 and was recognized by the Yale School of Management, CEO Institute as a Legends in Leadership Award in 2017. [22] [23]

In 2019, he received the Alexander Hamilton Award, [24] Columbia's highest honor for contributions to science and medicine and was recognized by Forbes as one of America’s 100 Most Innovative Leaders. [25]

Yancopoulos was recognized by Fortune in 2020 as one of the World's 25 Greatest Leaders: Heroes of the Pandemic. [26]

In 2021, Yancopoulos won the Roy Vagelos Humanitarian Award for REGEN-COV, Prix Galien Foundation [27] and the New York Intellectual Property Law Association's Inventors of the Year for REGEN-COV. [28]

Boards

Yancopoulos serves on a number of Boards, including on Regeneron's Board of Directors. He currently serves on the Columbia University Medical Center Board of Visitors, as Vice Chair starting in 2012; [29] the Board of Trustees for Cold Spring Harbor Laboratory, since 2015; [30] the Scientific Advisory Council, Alliance on Cancer Gene Therapy, since 2007; [31] the Scleroderma Research Foundation, Scientific Advisory Board, starting in 2004; [32] and the Pershing Square Cancer Research Alliance, Advisory Board, since 2018. [33]

Controversies

Concerns over Yancopoulos' 2020 personal and business related behavior pertaining to race and privilege have been reported. Yancopoulos has been criticized for commentary during a high school graduation speech he gave in 2020 in which he characterized the police as "scapegoats", challenged students to question "popular narratives", and use statistics and data to formulate their perspectives, within the context of social justice movements like the Black Lives Matter movement. [34] [35]

Also in 2020, Donald Trump and others in his administration were treated with REGEN-COV, Regeneron's experimental COVID-19 therapeutic, raising concerns that Regeneron had provided them with privileged access to the drug. [36] [37] At the time, the drug was undergoing clinical trials in humans and not yet under an FDA emergency use authorization (EUA). However, as is typical for experimental drugs, the FDA "expanded access" regulation, technically known as 21 CFR 312.310, allowed Trump's physicians to request "compassionate use" of REGN-COV. [38] Compassionate use is granted by the FDA (not the drug developer) to individual patients when it is determined that "the probable risk to the person from the investigational drug is not greater than the probable risk from the disease or condition." [39] REGN-COV was developed using the same patented VelocImmune technology which produced the world's first cure to the Ebola virus. [40] The successful track record of VelocImmune technology at producing safe and effective monoclonal antibody treatments against viruses presumably contributed to the FDA's decision to grant compassionate use to Donald Trump.

Yancopoulos received unusual and preferential treatment from New York state related to his personal COVID-19 testing. [41]

Key Papers

Related Research Articles

<span class="mw-page-title-main">Gefitinib</span> Medication used for cancer

Gefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR, but resistances to gefitinib can arise through other mutations. It is marketed by AstraZeneca and Teva.

<span class="mw-page-title-main">MuSK protein</span> Mammalian protein found in Homo sapiens

MuSK is a receptor tyrosine kinase required for the formation and maintenance of the neuromuscular junction. It is activated by a nerve-derived proteoglycan called agrin, which is similarly also required for neuromuscular junction formation.

<span class="mw-page-title-main">Tropomyosin receptor kinase B</span> Protein and coding gene in humans

Tropomyosin receptor kinase B (TrkB), also known as tyrosine receptor kinase B, or BDNF/NT-3 growth factors receptor or neurotrophic tyrosine kinase, receptor, type 2 is a protein that in humans is encoded by the NTRK2 gene. TrkB is a receptor for brain-derived neurotrophic factor (BDNF). The standard pronunciation for this protein is "track bee".

<span class="mw-page-title-main">Tropomyosin receptor kinase C</span> Protein-coding gene in the species Homo sapiens

Tropomyosin receptor kinase C (TrkC), also known as NT-3 growth factor receptor, neurotrophic tyrosine kinase receptor type 3, or TrkC tyrosine kinase is a protein that in humans is encoded by the NTRK3 gene.

<span class="mw-page-title-main">Agrin</span> Mammalian protein found in Homo sapiens

Agrin is a large proteoglycan whose best-characterised role is in the development of the neuromuscular junction during embryogenesis. Agrin is named based on its involvement in the aggregation of acetylcholine receptors during synaptogenesis. In humans, this protein is encoded by the AGRN gene.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

<span class="mw-page-title-main">Neurotrophin-3</span> Protein-coding gene in the species Homo sapiens

Neurotrophin-3 is a protein that in humans is encoded by the NTF3 gene.

<span class="mw-page-title-main">Bruton's tyrosine kinase</span> Kinase that plays a role in B cell development

Bruton's tyrosine kinase, also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development.

<span class="mw-page-title-main">ZAP70</span> Protein-coding gene in the species Homo sapiens

ZAP-70 is a protein normally expressed near the surface membrane of lymphocytes. It is most prominently known to be recruited upon antigen binding to the T cell receptor (TCR), and it plays a critical role in T cell signaling.

<span class="mw-page-title-main">Glycoprotein 130</span> Mammalian protein found in Homo sapiens

Glycoprotein 130 is a transmembrane protein which is the founding member of the class of tall cytokine receptors. It forms one subunit of the type I cytokine receptor within the IL-6 receptor family. It is often referred to as the common gp130 subunit, and is important for signal transduction following cytokine engagement. As with other type I cytokine receptors, gp130 possesses a WSXWS amino acid motif that ensures correct protein folding and ligand binding. It interacts with Janus kinases to elicit an intracellular signal following receptor interaction with its ligand. Structurally, gp130 is composed of five fibronectin type-III domains and one immunoglobulin-like C2-type (immunoglobulin-like) domain in its extracellular portion.

<span class="mw-page-title-main">Angiopoietin 1</span> Protein-coding gene in the species Homo sapiens

Angiopoietin 1 is a type of angiopoietin and is encoded by the gene ANGPT1.

<span class="mw-page-title-main">CD135</span> Protein-coding gene in the species Homo sapiens

Cluster of differentiation antigen 135 (CD135) also known as fms like tyrosine kinase 3, receptor-type tyrosine-protein kinase FLT3, or fetal liver kinase-2 (Flk2) is a protein that in humans is encoded by the FLT3 gene. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. CD135 is the receptor for the cytokine Flt3 ligand (FLT3L).

<span class="mw-page-title-main">Tyrosine kinase 2</span> Enzyme and coding gene in humans

Non-receptor tyrosine-protein kinase TYK2 is an enzyme that in humans is encoded by the TYK2 gene.

The ErbB family of proteins contains four receptor tyrosine kinases, structurally related to the epidermal growth factor receptor (EGFR), its first discovered member. In humans, the family includes Her1, Her2 (ErbB2), Her3 (ErbB3), and Her4 (ErbB4). The gene symbol, ErbB, is derived from the name of a viral oncogene to which these receptors are homologous: erythroblastic leukemia viral oncogene. Insufficient ErbB signaling in humans is associated with the development of neurodegenerative diseases, such as multiple sclerosis and Alzheimer's disease, while excessive ErbB signaling is associated with the development of a wide variety of types of solid tumor.

<span class="mw-page-title-main">Ephrin B2</span> Protein-coding gene in the species Homo sapiens

Ephrin-B2 is a protein that in humans is encoded by the EFNB2 gene.

<span class="mw-page-title-main">TEK tyrosine kinase</span> Protein-coding gene in the species Homo sapiens

Angiopoietin-1 receptor also known as CD202B is a protein that in humans is encoded by the TEK gene. Also known as TIE2, it is an angiopoietin receptor.

<span class="mw-page-title-main">EPH receptor A2</span> Protein-coding gene in humans

EPH receptor A2 is a protein that in humans is encoded by the EPHA2 gene.

<span class="mw-page-title-main">Anaplastic lymphoma kinase</span> Protein-coding gene in the species Homo sapiens

Anaplastic lymphoma kinase (ALK) also known as ALK tyrosine kinase receptor or CD246 is an enzyme that in humans is encoded by the ALK gene.

Joseph Schlessinger is a Yugoslav-born Israeli-American biochemist and biophysician. He is chair of the Pharmacology Department at Yale University School of Medicine in New Haven, Connecticut, as well as the founding director of the school's new Cancer Biology Institute. His area of research is signaling through tyrosine phosphorylation, which is important in many areas of cellular regulation, especially growth control and cancer. Schlessinger's work has led to an understanding of the mechanism of transmembrane signaling by receptor tyrosine kinases and how the resulting signals control cell growth and differentiation.

<span class="mw-page-title-main">Anthony R. Hunter</span> British-American biologist (born 1943)

Anthony Rex Hunter is a British-American biologist who is a professor of biology at the Salk Institute for Biological Studies and the University of California San Diego. His research publications list his name as Tony Hunter.

References

  1. "Exclusive: Biotech Regeneron on verge of big leagues". Reuters. May 12, 2010. Retrieved May 1, 2011.
  2. "George Yancopoulos". United States Patent and Trademark Office . Retrieved July 25, 2018.
  3. Toni Nasr (February 5, 2018). "Regeneron Investment: Healthcare With Wealthcare". Seeking Alpha .
  4. "Our Team". Regeneron Pharmaceuticals . Retrieved July 26, 2018.
  5. Ron Winslow (May 26, 2016). "Regeneron Named as Science Talent Search Sponsor". The Wall Street Journal.
  6. 1 2 3 4 "George Yancopoulos: Doing Well by Trying to Do Good". Scientific American. October 6, 2008. Retrieved May 1, 2011.
  7. "Dr. George D. Yancopoulos, Founding Scientist, Regeneron Laboratories, to Be Honored by Burke Rehabilitation Center". Burke Rehabilitation Hospital. May 29, 2013.
  8. "Cusp Speaker Series Presents: 2005-2006".
  9. "George D. Yancopoulos". National Academy of Sciences . Retrieved September 17, 2018.
  10. "How Nerve Meets Muscle and Begins to Talk". New York Times. May 21, 1996. Retrieved May 1, 2011.
  11. Matthew Herper (August 14, 2013). "How Two Guys From Queens Are Changing Drug Discovery". Forbes .
  12. Michael S. Krangel (December 1, 2015). "Beyond Hypothesis: Direct Evidence That V(D)J Recombination Is Regulated by the Accessibility of Chromatin Substrates". Journal of Immunology . 195 (11): 5103–5105. doi: 10.4049/jimmunol.1502150 . PMID   26589747. S2CID   39216064.
  13. "George D. Yancopoulos". Bloomberg L.P. Retrieved July 23, 2018.
  14. "Regeneron Founded by Two STS Alumni". Society for Science & the Public . Retrieved July 27, 2018.
  15. "Regeneron Genetics Center". 2023.
  16. Alex Philippidis (November 15, 2017). "Regeneron Genetics Center Surpasses 250K Exomes Sequenced, and Ramping Up". Genetic Engineering & Biotechnology News.
  17. Mathew, Herper. "Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief". forbes.com. Retrieved 28 July 2015.
  18. "Marc Tessier-Lavigne receives lifetime achievement award from biotech executives".
  19. "Dr. George D. Yancopoulos, Founding Scientist, Regeneron Laboratories, to Be Honored by Burke Rehabilitation Center". Burke Rehabilitation Hospital. 3 June 2013. Retrieved June 3, 2013.
  20. John Golden (November 22, 2016). "Regeneron's Schleifer, Yancopoulos share Entrepreneur of Year award". Westfair Online.
  21. "Advisory Council: George D. Yancopoulos, MD, PhD". LifeSci NYC. Retrieved July 31, 2018.
  22. Sofie Levine (May 30, 2018). "George Yancopoulos '76". The Science Survey.
  23. "Legend in Leadership Recipients". Yale School of Management. December 15, 2017.
  24. "Dr. George D. Yancopoulos CC'80, GSAS'86, VPS'87 honored at Alexander Hamilton Dinner". Columbia College. November 22, 2019.
  25. "#20 George Yancopoulos". Forbes. April 20, 2020.
  26. "#8 George Yancopoulos". Fortune. April 20, 2020.
  27. "Laureates since 2007". The Galien Foundation. October 13, 2022. Retrieved October 13, 2022.
  28. "Inventor of the Year Award". The New York Intellectual Property Law Association. October 13, 2022. Retrieved October 13, 2022.
  29. "Leadership and Administration". Columbia University. October 12, 2022. Retrieved October 12, 2022.
  30. "Regeneron's Dr. George D. Yancopoulos elected to Cold Spring Harbor Laboratory Board of Trustees". Cold Spring Harbor Laboratory. October 12, 2022. Retrieved October 12, 2022.
  31. "George D. Yancopoulos, MD, PhD". Alliance for Cancer Gene Therapy. October 12, 2022. Retrieved October 12, 2022.
  32. "Bio". Scleroderma Research Foundation. October 12, 2022. Retrieved October 12, 2022.
  33. "Prize Advisory Board". Pershing Square Sohn Cancer Research Alliance. October 12, 2022. Retrieved October 12, 2022.
  34. "Sy Mukherjee (July 2, 2020) "Regeneron's Billionaire Cofounder Criticized After 'All Lives Matter' Graduation Speech" Fortune" .
  35. "Leah Rosenbaum (June 30, 2020) "Regeneron's Billionaire Cofounder Criticized After 'All Lives Matter' Graduation Speech" Forbes". Forbes .
  36. Stolberg, Sheryl Gay (10 December 2020). "Sheryl Gay Stolberg (December 9, 2020) "Trump and Friends Got Coronavirus Care Many Others Couldn't" The New York Times". The New York Times.
  37. "Alison Bateman-House, et al. (October 8, 2020) "Trump's Regeneron Treatment Is a Tangled Ethical Mess" Barron's".
  38. "Jon Cohen (October 5, 2020) "Update: Here's what is known about Trump's COVID-19 treatment" Science". Science .
  39. "CFR - Code of Federal Regulations Title 21". U.S. Food & Drug Administration .
  40. "Our Rapid Response to COVID-19". Regeneron Pharmaceuticals .
  41. Goodman, J. David; Ferré-Sadurní, Luis; McKinley, Jesse (25 March 2021). "J. David Goodman, et al. (March 25, 2021) "Executive With Ties to Cuomo Got Special Access to Virus Testing" The New York Times". The New York Times.